Overview

Radiation Use During Vemurafenib Treatment

Status:
Withdrawn

Trial end date:
2022-08-01

Target enrollment:

Participant gender:

Summary

Patients are being asked to take part because they have melanoma that has spread to other organs in their body (metastatic). As part of this study, patients will receive radiation therapy and an approved drug (Vemurafenib).

Phase:

Phase 1

Details

Lead Sponsor:

University of Utah

Treatments:

Vemurafenib